

# Crop Protection

## European Regulatory Conference

7<sup>th</sup> & 8<sup>th</sup> March 2018

***Hotel Crowne Plaza***

B-1000 Brussels



For hotel booking, see: <https://aws.passkey.com/event/49492632/owner/7604429/home>


	<b><i>CONFERENCE TIMINGS</i></b>
<b>Wednesday:</b>	
0900-1200	4 workshops
1200-1300	Lunch
1300-1830	Sessions 1 & 2
1830-2000	Panel Debate
2000-2200	Conference Dinner
<b>Thursday:</b>	
0830-1330	Sessions 3 & 4
1330 -	Lunch
1400-1530	Brexit workshop

## Day 1: Wednesday 7<sup>th</sup> March

**08h15** | **Registration**

### Workshops

<u>Human Health (&amp; risk assessment developments)</u>	<u>Product efficacy &amp; precision farming</u>		<u>Legal and intellectual property</u>	<u>Political and agricultural policy</u>
Workshop sponsored by: 	Workshop sponsored by: 			
<b>Chair: Vincent Dreze, Eurofins</b>	<b>Chair: Norbert Weissmann, SCC</b>	08h50	<b>Chair: Spyros Pappas, Pappas &amp; Associates</b>	<b>Chair: Graeme Taylor, ECPA</b>
Human health challenges for industry (e.g. CRA, genotox) – <b>Phil Botham, Syngenta</b>	Precision farming developments <b>Vik Vandecaveye, CNH Industrial</b>	09h00	In the battle for confidentiality – our way through the Courts - <b>Gerardine Garcon, BASF</b>	Political challenges and communication in Withorwithout campaign – <b>Philip Weiss, ZN Consulting</b>
EFSA update on HH – <b>Andrea Terron</b>	Precision farming – what does it mean for the PPP uses and the approval process? <b>Martin Schaefer, BASF</b>	09h10	Voluntary Disclosure of Studies by Industry – Legal Aspects – <b>Niklas Pieper, Bayer</b>	Cumulative Impact Assessment – Update – <b>Anne van Drunen-Little, Steward Redqueen</b>
		09h20	Recent case law on protection of regulatory data – <b>Claudio Mereu, FieldFisher</b>	
Questions and Answers	Questions and Answers	09h30	Questions and Answers	Questions and Answers
		09h40		
Coffee Break	Coffee Break	09h50		
		10h00		
		10h10		
		10h20		
		10h30		
Exposure assessment for epidemiological studies on PPPs: <b>Karen Galea (IOM)</b>	Simplify efficacy for today and the future – <b>Beth Hall, Syngenta</b>	10h40	Recent EU case law relevant for the PPP sector: <b>Irene Antypas, Ashurst</b>	SUD, IPM and low-risk – Viewpoint of the bio-control industry. – <b>David Cary, IBMA</b>
		10h50		
Worker and bystander/resident exposure models – Industry input - <b>Alistair Morriss, DowDuPont</b>	Simplify efficacy, today and the future – a minor use perspective – <b>Jeroen Meeussen, MUCF</b>	11h00	Import tolerances – <b>Patrick Reimer, Syngenta</b>	SMART resistance management project – <b>Maria Torne, DowDuPont</b>
		11h10		
Tox21 / Risk21 – <b>Tina Mehta, DowDuPont</b>	Adapting to the environment in product registrations: <b>Dr. Joachim Kranz, SCC</b>	11h20	SPCs and EU Unitary patents – <b>Bettina Wanner, Bayer</b>	Organic farmer’s viewpoint - <b>Stephen Parsley, UK</b>
		11h30		
Panel discussion with CAAT	Panel discussion With Cristina Alfaro, Suterra	11h40	Panel discussion	Panel discussion
		11h50		
Conclusions & close	Conclusions & close	12h00	Conclusions & close	Conclusions & close

<b>Day 1: Wednesday 7<sup>th</sup> March</b>	
<b>12h00</b>	<b>Lunch</b>
13h00	<b>Session 1: Overview of current challenges</b> <b>Chairman: Coralie van Breukelen-Groeneveld, Bayer</b>
13h10	Welcome address - <b>Jean-Philippe Azoulay, ECPA Director General</b>
13h20	Update on implementation of Regulation 1107/2009 - <b>Klaus Berend, DG SANTE</b>
13h50	Regulation 1107/2009 - challenges for today and the future - <b>Martyn Griffiths, Bayer</b>
14h15	Main issues for national authorities in the AS and product evaluations? - <b>Barbara Oliveira, Portugal</b>
14h40	Opportunities to improve the legislation and implementation? - <b>Pavel Minar, Czech Republic</b>
15h05	Question and answer
<b>15h30</b>	<b>Coffee break</b>
	<b>Session 2: Active substance evaluation update</b>
16h00	AS review programme - <b>Wolfgang Reinert, DG SANTE</b>
16h25	MS challenges in AS review evaluation: improving cooperation between Member States and EFSA – <b>Luuk van Duijn, CTGB</b>
16h50	EFSA update on active substances review – <b>José Tarazona or Benedicte Vagenende, EFSA</b>
17h15	The risk assessment output – what options for risk managers? – <b>Martin Streloke, BVL, Germany</b>
17h40	Key hurdles from assessment to decision making - <b>Jane West, Syngenta</b>
18h05	Panel discussion
<b>18h30</b>	<b>Pre-debate drinks</b>
19h00	<b>Evening debate: Does science still have a role in EU decision making on food policy issues?</b> <b>Chair: [tbc]</b> <ul style="list-style-type: none"> <li>➤ Philippe Lamberts MEP</li> <li>➤ Hubert Deluyker</li> <li>➤ Paul Leonard, BASF</li> </ul>
20h00	<b>Conference dinner</b>
	Sponsored by: 

<b>Day 2: Thursday 8<sup>th</sup> March</b>	
	<b>Session 3: Product evaluation challenges</b>
08h30	Chairman's introduction
08h35	Article 43 - where's the silver bullet? - <b>Christian Prohaska, AGES, Austria</b>
09h00	South zone update – <b>J-L Alonso Prados (tbc)</b>
09h25	Northern zone update - <b>Vibeke Moeller, Denmark</b>
09h50	Industry view on key challenges in product authorisation – <b>Jeanne Roederer, ADAMA</b>
10h10	Challenges and focus of the Post approval issue group – <b>Darren Flynn, CRD</b>
10h25	Panel discussion
<b>10h45</b>	<b>Coffee break</b>
	<b>Session 4: Science update &amp; Legislative review</b>
	<b>Science update</b>
11h15	Update on endocrine disruption and other scientific guidance issues - <b>Karin Nienstedt, DG SANTE</b>
11h40	Scientific developments likely to impact on regulatory implementation - <b>Gábor Tőkés, Hungary</b>
12h00	Industry viewpoint on guidance documents under discussion – <b>Peter Campbell, Syngenta</b>
12h20	Panel discussion
	<b>Legislative review</b>
12h40	Introduction to the panel discussion by chairman
12h50	Panel discussion with: <ul style="list-style-type: none"> <li>➤ Klaus Berend</li> <li>➤ José Tarazona</li> <li>➤ Luuk van Dijn</li> <li>➤ Industry</li> </ul>
13h25	CONCLUSION AND CLOSE
<b>13h30</b>	<b>Lunch</b>
	<b>Workshop: Likely implications of Brexit</b>
14h00	Introduction
14h05	Current status, impact on EU process and likely implications in PPP evaluations – <b>Dave Bench, CRD</b>
14h35	The industry viewpoint in the UK – <b>Janet Williams, Bayer &amp; Beth Cannell, CPA</b>
15h00	Panel discussion; Questions and answers
15h30	Close